SPARK Europe Webinar Series | Hans Platteeuw: “What Is Drug Repurposing and Why Is It Relevant?”

Hans Platteeuw will first give a general introduction into drug repurposing and talk about the pros and cons compared to developing a new chemical entity as drug. Further, based on two use-cases, we will learn about opportunities but also challenges for repurposing and possible solutions.

Platteeuw is a chemist by training. He has a long-standing experience in product development in both the innovator, generics and value-added medicines industry. He is a founder and Chief Scientific Officer of Galenicap, a company fully dedicated to the development of New Therapeutic Entities. Galenicap acts as an incubator that starts from an academic concept to address a clinical need via existing medications, then transforms the concept into an unique pharmaceutical product with clinical proven endpoints of efficacy and safety and that verifies that all requirements are fulfilled to make the product ready to be available for patients globally including regulatory, intellectual property and financial considerations.

SPARK Europe Webinar Series

The webinar series is organized by the different SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Denmark, SPARK Poland, SPARK Tel Aviv, SPARK Zürich and SPARK at the Faculty of Medicine, Masaryk University.

The series covers topics from design thinking to challenges in selling complex high-tech products from top-quality speakers around Europe and the US.

The online lectures take place once per month on Wednesday at 4-5 pm CET, and are open for all students and employees of SPARK associated organizations.

About SPARK-BIH and SPARK Europe

SPARK is an initiative created at Stanford University, to overcome challenges associated with translation of academic discoveries.

SPARK-BIH is located in Berlin and supports academic inventors with tailored education, mentorship and funding. The purpose of the program is to de-risk projects with high potential impact and accelerate the translation of academic inventions into outstanding medical products including drugs, diagnostics and medical devices.

SPARK Europe is the joint network of SPARK sites all over Europe plus Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Denmark, SPARK Poland and SPARK Tel Aviv. It aims to fulfill SPARK’s mission of improving human health by uniting academics and industry experts around the globe to generate an efficient, effective and exciting pathway for the translation of academic discoveries and innovative solutions through education and project support.